Stay updated with breaking news from Biolexa Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hoth Therapeutics (NASDAQ:HOTH – Get Rating) had its target price cut by EF Hutton Acquisition Co. I from $33.00 to $14.00 in a research note published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Hoth Therapeutics Trading Down 4.3 % Shares of Hoth Therapeutics stock opened at $1.99 on […]
Oncorus (NASDAQ:ONCR – Get Rating) and Hoth Therapeutics (NASDAQ:HOTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility and Risk Oncorus has a beta of 4.27, meaning […]
Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 380,700 shares, an increase of 404.2% from the February 28th total of 75,500 shares. Based on an average daily volume of 5,290,000 shares, the short-interest ratio is […]
Share this article Share this article NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne. The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pa...